Top Buy Stocks
Sign In
NASDAQ:ACAD
ACADIA Pharmaceuticals Inc. Stock News
$17.60
+0.440 (+2.56%)
At Close: May 15, 2025
ACADIA Pharmaceuticals: Advancing On Several Fronts
12:01pm, Tuesday, 13'th May 2025
ACADIA Pharmaceuticals posted better-than-expected Q1 results earlier this month. The company has a rock solid balance sheet and advancing a couple of key drug candidates within its pipeline. An updat
Acadia Pharmaceuticals (ACAD) Tops Q1 Earnings and Revenue Estimates (Revised)
07:30pm, Friday, 09'th May 2025
Acadia Pharmaceuticals (ACAD) came out with quarterly earnings of $0.11 per share, beating the Zacks Consensus Estimate of $0.10 per share. This compares to earnings of $0.10 per share a year ago.
Acadia Q1 Earnings Beat, Nuplazid & Daybue Sales Drive Revenue Growth
11:40am, Thursday, 08'th May 2025
ACAD reports encouraging first-quarter results as earnings and revenues beat estimates, driven by year-over-year growth in Nuplazid and Daybue sales.
ACADIA Pharmaceuticals Inc. (ACAD) Q1 2025 Earnings Conference Call Transcript
08:10pm, Wednesday, 07'th May 2025
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD ) Q1 2025 Earnings Conference Call May 7, 2025 4:30 PM ET Company Participants Al Kildani - SVP of IR & Corporate Communications Catherine Owen Adams - CEO Tom
Acadia Pharmaceuticals (ACAD) Tops Q1 Earnings and Revenue Estimates
06:41pm, Wednesday, 07'th May 2025
Acadia Pharmaceuticals (ACAD) came out with quarterly earnings of $0.11 per share, beating the Zacks Consensus Estimate of $0.10 per share. This compares to earnings of $0.10 per share a year ago.
Acadia Pharmaceuticals Reports First Quarter 2025 Financial Results and Operating Overview
04:05pm, Wednesday, 07'th May 2025
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced its financial results for the first quarter ended March 31, 2025. “2025 is off to a strong start for Acadia, ac
Acadia Pharmaceuticals to Participate in the BofA Securities 2025 Health Care Conference
04:05pm, Monday, 05'th May 2025
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate in a fireside chat at the BofA Securities 2025 Health Care Conference on Tuesday, May 13
5 Drug/Biotech Stocks Likely to Outperform Q1 Earnings Estimates
10:15am, Monday, 05'th May 2025
Let us look at some drug/biotech stocks, NVO, PCRX, RARE, ACAD and DNLI, which are poised to beat on first-quarter 2025 earnings.
Earnings Preview: Acadia Pharmaceuticals (ACAD) Q1 Earnings Expected to Decline
11:07am, Wednesday, 30'th Apr 2025
Acadia (ACAD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Acadia Pharmaceuticals to Announce First Quarter Financial Results on May 7, 2025
04:05pm, Wednesday, 23'rd Apr 2025
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report first quarter financial results on Wednesday, May 7, 2025, after the close of the U.S. financ
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Friday, 11'th Apr 2025
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on April 3, 2025, the Compensation Committee of Acadia's Board of Directors (the “Committee”) granted in
Acadia (ACAD) Stock Jumps 6.1%: Will It Continue to Soar?
10:35am, Thursday, 10'th Apr 2025
Acadia (ACAD) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Acadian upgraded to Equal Weight from Underweight at Morgan Stanley
05:17am, Monday, 07'th Apr 2025
Morgan Stanley upgraded Acadian Asset Management to Equal Weight from Underweight with a price target of $26, up from $25. The company's skew to overseas assets will insulate its possible downside to
Why Is Acadia (ACAD) Down 11.1% Since Last Earnings Report?
12:36pm, Friday, 28'th Mar 2025
Acadia (ACAD) reported earnings 30 days ago. What's next for the stock?
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Friday, 14'th Mar 2025
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on March 5, 2025, the Compensation Committee of Acadia's Board of Directors (the “Committee”) granted in
